BIOS Stock Overview
A biotech company, focuses on developing clinical assets. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioSenic S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0061 |
| 52 Week High | €0.098 |
| 52 Week Low | €0.0038 |
| Beta | -2.74 |
| 11 Month Change | -53.08% |
| 3 Month Change | -31.46% |
| 1 Year Change | -85.81% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOS | BE Biotechs | BE Market | |
|---|---|---|---|
| 7D | 1.7% | -5.0% | -1.6% |
| 1Y | -85.8% | 3.0% | 2.0% |
Return vs Industry: BIOS underperformed the Belgian Biotechs industry which returned 3% over the past year.
Return vs Market: BIOS underperformed the Belgian Market which returned 2% over the past year.
Price Volatility
| BIOS volatility | |
|---|---|
| BIOS Average Weekly Movement | 24.1% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in BE Market | 6.3% |
| 10% least volatile stocks in BE Market | 2.1% |
Stable Share Price: BIOS's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: BIOS's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.biosenic.com |
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.
BioSenic S.A. Fundamentals Summary
| BIOS fundamental statistics | |
|---|---|
| Market cap | €1.65m |
| Earnings (TTM) | -€7.44m |
| Revenue (TTM) | €2.87m |
0.6x
P/S Ratio-0.2x
P/E RatioIs BIOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOS income statement (TTM) | |
|---|---|
| Revenue | €2.87m |
| Cost of Revenue | €0 |
| Gross Profit | €2.87m |
| Other Expenses | €10.31m |
| Earnings | -€7.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 100.00% |
| Net Profit Margin | -259.05% |
| Debt/Equity Ratio | -125.9% |
How did BIOS perform over the long term?
See historical performance and comparison